Literature DB >> 16102573

Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse.

Kathryn Haskins1.   

Abstract

T-cell clones that can efficiently transfer diabetes to prediabetic nonobese diabetic (NOD) mice provide a powerful approach to dissecting the autoimmune disease process and for investigating immunoregulation. Diabetogenic T-cell clones carried in culture allow for detailed analysis of T-cell effector function and in vivo activity, and thus the contribution of a single clonotype to pathogenesis can be studied. As T cells comprising most or all of the repertoire in T-cell receptor transgenic (TCR-Tg) mice, diabetogenic T-cell clones have led to new variations on the NOD mouse model of autoimmune disease. T-cell clones are being used to screen peptide libraries and proteomic arrays to identify the autoantigens that drive these clones in vivo and to extend our knowledge of the processes that give rise to these antigens. With the identification of peptide agonists and natural ligands, the development of MHC-peptide multimers has been possible. These reagents can track T cells in vivo and thus provide new approaches for disease diagnosis and therapy as well as a versatile set of tools for basic research on how T cells contribute to autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102573     DOI: 10.1016/S0065-2776(05)87004-X

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  42 in total

Review 1.  HIPs and HIP-reactive T cells.

Authors:  T A Wiles; T Delong
Journal:  Clin Exp Immunol       Date:  2019-06-17       Impact factor: 4.330

2.  Simultaneous Recognition of Allogeneic MHC and Cognate Autoantigen by Autoreactive T Cells in Transplant Rejection.

Authors:  Adam L Burrack; Laurie G Landry; Janet Siebert; Marilyne Coulombe; Ronald G Gill; Maki Nakayama
Journal:  J Immunol       Date:  2018-01-08       Impact factor: 5.422

Review 3.  Insulin as a key autoantigen in the development of type 1 diabetes.

Authors:  Maki Nakayama
Journal:  Diabetes Metab Res Rev       Date:  2011-11       Impact factor: 4.876

4.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

5.  Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion.

Authors:  Thomas Delong; Timothy A Wiles; Rocky L Baker; Brenda Bradley; Gene Barbour; Richard Reisdorph; Michael Armstrong; Roger L Powell; Nichole Reisdorph; Nitesh Kumar; Colleen M Elso; Megan DeNicola; Rita Bottino; Alvin C Powers; David M Harlan; Sally C Kent; Stuart I Mannering; Kathryn Haskins
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

6.  Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity.

Authors:  Joseph Cantor; Marina Slepak; Nil Ege; John T Chang; Mark H Ginsberg
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

Review 7.  The anti-insulin trimolecular complex in type 1 diabetes.

Authors:  Aaron W Michels; Maki Nakayama
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-08       Impact factor: 3.243

8.  Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice.

Authors:  Rocky L Baker; Thomas Delong; Gene Barbour; Brenda Bradley; Maki Nakayama; Kathryn Haskins
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

9.  Pathogenicity of T helper 2 T-cell clones from T-cell receptor transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha.

Authors:  Jing He; Kathryn Haskins
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

10.  A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis.

Authors:  Kristen N Cordova; Van C Willis; Kathryn Haskins; V Michael Holers
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.